Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus

Antiviral Research

Volumn 72, Issue 2, 2006, Pages 157-161

  Suzuki, Mikiko ^a   Okuda, Tomoko ^a   Shiraki, Kimiyasu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Acyclovir; Drug interactions; Herpes simplex viruses; Synergism; Varicella zoster virus; Vidarabine

Indexed keywords

ACICLOVIR; DNA POLYMERASE; PHOSPHONOACETIC ACID; VIDARABINE;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CHICKENPOX; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VARICELLA ZOSTER VIRUS;

ACYCLOVIR; ANTIVIRAL AGENTS; CELL LINE; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; GENE DELETION; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS 3, HUMAN; HUMANS; PHOSPHONOACETIC ACID; PHOSPHORYLATION; PLAQUE ASSAY; THYMIDINE KINASE; VIDARABINE; VIRAL PROTEINS;

HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 3; SIMPLEXVIRUS;

EID: 33748301929     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.001     Document Type: Article

References (35)

1. Biron K.K., and Elion G.B. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob. Agents Chemother. 18 (1980) 443-447
2. Coen D.M., and Schaffer P.A. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 2265-2269
3. Cohen G.M. Ribonucleotide reductase activity of synchronized KB cells infected with herpes simplex virus. J. Virol. 9 (1972) 408-418
4. Collum L.M., O'Connor M., and Logan P. Comparison of the efficacy and toxicity of acyclovir and of adenine arabinoside when combined with dilute betamethasone in herpetic disciform keratitis: preliminary results of a double-blind trial. Trans. Ophthalmol. Soc. U.K. 103 (1983) 597-599
5. de Rudder. Jr., and de Garilhe M.P. Inhibitory effect of some nucleosides on the growth of various human viruses in tissue culture. Antimicrob. Agents Chemother. 5 (1965) 578-584
6. Dubbs D.R., and Kit S. Mutant strains of herpes simplex deficient in thymidine kinase-inducing activity. Virology 22 (1964) 493-502
7. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., and Schaeffer H.J. Selectivity of action of an antiherpetic agent 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 5716-5720
8. Gephart J.F., and Lerner A.M. Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine and arabinosyladenine 5′-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis. Antimicrob. Agents Chemother. 19 (1981) 170-178
9. Kamiyama T., Kurokawa M., and Shiraki K. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J. Gen. Virol. 82 (2001) 2761-2765
10. Kumano Y., Yamamoto M., and Mori R. Protection against herpes simplex virus infection in mice by recombinant murine interferon-β in combination with antibody. Antiviral Res. 7 (1987) 289-301
11. Kurokawa M., Hozumi T., Tsurita M., Kadota S., Namba T., and Shiraki K. Biological characterization of eugenin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. J. Pharmacol. Exp. Ther. 297 (2001) 372-379
12. Kurokawa M., Nagasaka K., Hirabayashi T., Uyama S., Sato H., Kageyama T., Kadota S., Ohyama H., Hozumi T., Namba T., and Shiraki K. Efficacy of traditional herbal medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo. Antiviral Res. 27 (1995) 19-37
13. Kurokawa M., Ochiai H., Nagasaka K., Neki M., Xu H., Kadota S., Sutardjo S., Matsumoto T., Namba T., and Shiraki K. Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res. 22 (1993) 175-188
14. Langelier Y., and Buttin G. Characterization of ribonucleotide reductase induction in BHK-21/C13 Syrian hamster cell line upon infection by herpes simplex virus (HSV). J. Gen. Virol. 57 (1981) 21-31
15. Larder B.A., and Darby G. Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir. Antimicrob. Agents Chemother. 29 (1986) 894-898
16. Miwa N., Kurosaki K., Yoshida Y., Kurokawa M., Saito S., and Shiraki K. Comparative efficacy of acyclovir and vidarabine on the replication of varicella-zoster virus. Antiviral Res. 65 (2005) 49-55
17. Muller W.E.G., Zahn R.K., Beyer R., and Falke D. 9-β-d-arabinofuranosyladenine as a tool to study herpes simplex virus DNA replication in vitro. Virology 76 (1977) 787-796
18. Muller W.E.G., Zahn R.K., Bittlingmaier K., and Falke D. Inhibition of herpesvirus DNA synthesis by 9-β-d-arabinofuranosyladenine in cellular and cell-free systems. Ann. N.Y. Acad. Sci. 284 (1977) 34-48
19. Okuda T., Kurokawa K., Matsuo K., Honda M., Niimura M., and Shiraki K. Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus. J. Med. Virol. 72 (2004) 112-120
20. Pelling J.C., Drach J.C., and Shipman Jr. C. Internucleotide incorporation of arabinosyladenine into herpes simplex virus and mammalian cell DNA. Virology 109 (1981) 323-335
21. Reardon J.E., and Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J. Biol. Chem. 264 (1989) 7405-7411
22. Reusser P., Cordonnier C., Einsele H., Engelhard D., Link D., Locasciulli A., and Ljungman P. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 17 (1996) 813-817
23. Schabel Jr. F.M. The antiviral activity of 9-β-d-arabinofuranosyladenine (ARA-A). Chemotherapy 13 (1968) 321-338
24. Schwartz P.M., Novack J., Shipman Jr. C., and Drach J.C. Metabolism of arabinosyladenine in herpes simplex virus-infected and uninfected cells. Correlation with inhibition of DNA synthesis and role in antiviral selectivity. Biochem. Pharmacol. 33 (1984) 2431-2438
25. Shepp D.H., Dandliker P.S., and Meyers J.D. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. New Engl. J. Med. 314 (1986) 208-212
26. Shipman Jr. C., Smith S.H., Carlson R.H., and Drach J.C. Antiviral activity of arabinosyladenine and arabinosylhypoxanthine in herpes simplex virus infected KB cells: selective inhibition of viral deoxyribonucleic acid synthesis in synchronized suspension cultures. Antimicrob. Agents Chemother. 9 (1976) 120-127
27. Shiraki K., Namazue J., Okuno T., Yamanishi K., and Takahashi M. Novel sensitivity of acyclovir resistant varicella-zoster virus to antiherpetic drugs. Antiviral Chem. Chemother. 1 (1990) 373-376
28. Shiraki K., Okuno T., Yamanishi K., and Takahashi M. Polypeptides of varicella-zoster virus (VZV) and immunological relationship of VZV and herpes simplex virus (HSV). J. Gen. Virol. 61 (1982) 255-269
29. Shiraki K., Yamanishi K., and Takahashi M. Susceptibility to acyclovir of Oka-strain varicella vaccine and vaccine-derived viruses isolated from immunocompromised patients. J. Infect. Dis. 150 (1984) 306-307
30. Shiraki K., Yoshida Y., Asano Y., Yamanishi K., and Takahashi M. Pathogenic tropism of varicella-zoster virus to primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblasts. J. Infect. Dis. 188 (2003) 1875-1877
31. Shope T.C., Kauffman R.E., Bowman D., and Marcus E.L. Pharmacokinetics of vidarabine in the treatment of infants and children with infections due to herpesviruses. J. Infect. Dis. 148 (1983) 721-725
32. Whitley R., Arvin A., Prober C., Burchett S., Corey L., Powell S., Plotkin S., Starr S., Alford C., Conner J., Jacobs R., Nahmias A., Soong S.-J., and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. New Engl. J. Med. 324 (1991) 444-449
33. Whitley R.J., Ch'ien L.T., Dolin R., Galasso G.J., and Alford Jr. C.A. Adenine arabinoside therapy of herpes zoster in the immunosuppressed. New Engl. J. Med. 294 (1976) 1193-1199
34. Whitley R.J., Gnann Jr. J.W., Hinthorn D., Liu C., Pollard R.B., Hayden F., Mertz G.J., Oxman M., and Soong S.J. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. J. Infect. Dis. 165 (1992) 450-455
35. Yoshida Y., Li Z.-H., Kurokawa M., Kawana T., Imakita M., and Shiraki K. Growth of herpes simplex virus in epidermal keratinocytes determines cutaneous pathogenicity in mice. J. Med. Virol. 75 (2005) 421-426